Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nadunolimab and Toripalimab in Chemotherapy-refractory Metastatic MSS Colorectal Cancer
NCT07281716Phase 2Recruiting
- Start
- Dec 2025
- Primary completion
- Dec 2028
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of nadunolimab, toripalimab in colorectal cancer (CRC). Started Dec 2025; status: recruiting.
02
Drugs
nadunolimabtoripalimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07281716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07281716.